Baxter International Inc. BAX
Verdict: Sell. Fair value $17.38 against a price of $20.02 on 5 Jan 2026, 13% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power.
The case against: Macro headwinds could impact growth. Valuation multiple compression risk.
Main risks
- Severe leverage profile: Total Debt ($13.45B) exceeds Market Cap ($10.3B) with alarming Net Debt/EBITDA >17x based on TTM proxy.
- Deteriorating profitability: Negative TTM Net Income and Proxy EBIT indicate operational struggles or significant impairments.
- Revenue contraction: 3-year CAGR is negative (-4.3%), failing to return to 2021 peak levels ($12.15B).
- Near-term debt maturity concerns
- Low interest coverage (-0.4x)
- Market volatility